Uptake Inhibitors but not Substrates Induce Protease Resistance in Extracellular Loop Two of the Dopamine Transporter

Molecular Pharmacology

Volumn 65, Issue 3, 2004, Pages 692-701

  Gaffaney, Jon D ^a   Vaughan, Roxanne A ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; BENZATROPINE; COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; MAZINDOL; NOMIFENSINE; NORADRENALIN UPTAKE INHIBITOR; PROTEINASE; SEROTONIN UPTAKE INHIBITOR; TRITIUM; TRYPSIN; VANOXERINE; ZINC;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CORPUS STRIATUM; DEGLYCOSYLATION; DOPAMINE UPTAKE; ENZYME ACTIVE SITE; IMMUNOBLOTTING; LIGAND BINDING; LIPID BILAYER; MALE; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; RAT; SYNAPTOSOME;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BIOLOGICAL TRANSPORT; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; IMMUNOBLOTTING; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE POTENTIALS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMES; TRYPSIN;

EID: 1342265784     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.3.692     Document Type: Article

References (47)

1. 2+ pump does not separate from the main catalytic fragments after proteolysis. Biochim Biophys Acta 1464:127-134.
2. Adkins EM, Barker EL, and Blakely RD (2001) Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Mol Pharmacol 59:514-523.
3. Barker EL, Moore KR, Rakhshan F, and Blakely RD (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci 19:4705-4717.
4. Barker EL, Perlman MA, Adkins EM, Houlihan WJ, Pristupa ZB, Niznik HB, and Blakely RD (1998) High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J Biol Chem 273:19459-19468.
5. Bibi E and Kaback HR (1990) In vivo expression of the lacY gene in two segments leads to functional lac permease. Proc Natl Acad Sci USA 87:4325-4329.
6. Blaustein MP and Goldring JM (1975) Membrane potentials in pinched-off presynaptic nerve terminals monitored with a fluorescent probe: evidence that synaptosomes have potassium diffusion potentials. J Physiol 247:589-615.
7. Brauner T, Hulser DF, and Strasser RJ (1984) Comparative measurements of membrane potentials with microelectrodes and voltage-sensitive dyes. Biochim Biophys Acta 771:208-216.
8. Buck KJ and Amara SG (1994) Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4- phenylpyridinium. Proc Natl Acad Sci USA 91:12584-12588.
9. Buck KJ and Amara SG (1995) Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol Pharmacol 48:1030-1037.
10. Chen JG, Sachpatzidis A, and Rudnick G (1997) The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J Biol Chem 272:28321-28327.
11. Chen N, Ferrer JV, Javitch JA, and Justice JB Jr (2000) Transport-dependent accessibility of a cytoplasmic loop cysteine in the human dopamine transporter. J Biol Chem 275:1608-1614.
12. Chen N and Reith ME (2000) Structure and function of the dopamine transporter. Eur J Pharmacol 405:329-339.
13. Chen N, Sun L, and Reith ME (2002) Cationic interactions at the human dopamine transporter reveal binding conformations for dopamine distinguishable from those for the cocaine analog 2 alpha-carbomethoxy-3 alpha-(4- fluorophenyl)tropane. J Neurochem 81:1383-1393.
14. Chen N, Vaughan RA, and Reith ME (2001) The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J Neurochem 77:1116-1127.
15. Dodd PR, Hardy JA, Oakley AE, Edwardson JA, Perry EK, and Delaunoy JP (1981) A rapid method for preparing synaptosomes: comparison, with alternative procedures. Brain Res 226:107-118.
16. Ferrer JV and Javitch JA (1998) Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc Natl Acad Sci USA 95:9238-9243.
17. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, and Caron MG (1994) Delineation of discrete domains for substrate, cocaine and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 269:15985-15988.
18. Grunewald M and Kanner B (1995) Conformational changes monitored on the glutamate transporter GLT-1 indicate the existence of two neurotransmitter-bound states. J Biol Chem 270:17017-17024.
19. Heikkila RE and Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol 103: 241-248.
20. 2+ binding properties after removal of cytoplasmic fragments by proteinase K? J Biol Chem 270:20123-20134.
21. Krueger BK (1990) Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J Neurochem 55:260-267.
22. Kuhar MJ, Ritz MC, and Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299-302.
23. Lee SH, Chang MY, Jeon DJ, Oh DY, Son H, Lee CH, and Lee YS (2002) The functional domains of dopamine transporter for cocaine analog, CFT binding. Exp Mol Med 34:90-94.
24. Lee SH, Chang MY, Lee KH, Park BS, Lee YS, and Chin HR (2000) Importance of valine at position 152 for the substrate transport and 2β- carbomethoxy-3β-(4-fluorophenyl)tropane binding of dopamine transporter. Mol Pharmacol 57:883-889.
25. Lee SH, Kang SS, Son H, and Lee YS (1998) The region of dopamine transporter encompassing the 3rd transmembrane domain is crucial for function. Biochem Biophys Res Commun 246:347-352.
26. Lin Z, Itokawa M, and Uhl GR (2000a) Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition and expression. FASEB J 14:715-728.
27. Lin Z, Wang W, and Uhl GR (2000b) Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains. Mol Pharmacol 58:1581-1592.
28. 2+-binding site. J Biol Chem 274:36928-36934.
29. Loo TW and Clarke DM (1994) Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J Biol Chem 269:7750-7755.
30. Mabjeesh NJ and Kanner BI (1993) The substrates of a sodium- and chloride-coupled gamma-aminobutyric acid transporter protect multiple sites throughout the protein against proteolytic cleavage. Biochemistry 32:8540-8546.
31. Norregaard L, Frederiksen D, Nielsen EO, and Gether U (1998) Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO (Eur Mol Biol Organ) J 17:4266-4273.
32. Norregaard L, Loland CJ, and Gether U (2003) Evidence for distinct sodium, dopamine and cocaine dependent conformational changes in transmembrane segments 7 and 8 of the dopamine transporter. J Biol Chem.
33. 2+ influx through voltage-dependent calcium channels. J Neurochem 76:341-350.
34. 125I]RTI-82 labeled 3XFLAG6XHIShDAT. Soc Neurosci Abstr 898.17.
35. Reith ME, Berfield JL, Wang LC, Ferrer JV, and Javitch JA (2001) The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 276:29012-29018.
36. Reith ME, de Costa B, Rice KC, and Jacobson AE (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935 and dopamine to the dopamine transporter. Eur J Pharmacol 227:417-425.
37. Reith ME and Selmeci G (1992) Radiolabeling of dopamine uptake sites in mouse striatum: comparison of binding sites for cocaine, mazindol and GBR 12935. Naunyn-Schmiedeberg's Arch Pharmacol 345:309-318.
38. Smicun Y, Campbell SD, Chen MA, Gu H, and Rudnick G (1999) The role of external loop regions in serotonin transport. Loop scanning mutagenesis of the serotonin transporter external domain. J Biol Chem 274:36058-36064.
39. Stephan MM, Chen MA, Penado KM, and Rudnick G (1997) An extracellular loop region of the serotonin transporter may be involved in the translocation mechanism. Biochemistry 36:1322-1328.
40. Vaughan RA (1995) Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol Pharmacol 47:956-964.
41. Vaughan RA, Agoston GE, Lever JR, and Newman AH (1999) Differential binding of tropane-based photoaffinity ligands on the dopamine transporter. J Neurosci 19: 630-636.
42. Vaughan RA, Gaffaney JD, Lever JR, Reith ME, and Dutta AK (2001) Dual incorporation of photoaffinity ligands on dopamine transporters implicates proximity of labeled domains. Mol Pharmacol 59:1157-1164.
43. Vaughan RA, Huff RA, Uhl GR, and Kuhar MJ (1997) Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem 272:15541-15546.
44. Vaughan RA and Kuhar MJ (1996) Dopamine transporter ligand binding domains. Structural and functional properties revealed by limited proteolysis. J Biol Chem 271:21672-21680.
45. Wiener HL and Reith ME (1992) Determination of radioligand specific activity using competition binding assays. Anal Biochem 207:58-62.
46. Zhang Z, Huang JM, Turner MR, Rhinehart KL and Pallone TL (2001) Role of chloride in constriction of descending vasa recta by angiotensin II. Am J Physiol 280:R1878-R1886.
47. Zou MF, Kopajtic T, Katz JL, Wirtz S, Justice JB Jr, and Newman AH (2001) Novel tropane-based irreversible ligands for the dopamine transporter. J Med Chem 44:4453-4461.